tradingkey.logo
搜索

enVVeno Medical Corp

NVNO
添加自选
11.110USD
+0.310+2.80%
收盘 07/02, 13:00美东报价延迟15分钟
7.29M总市值
亏损市盈率 TTM

enVVeno Medical Corp

11.110
+0.310+2.80%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.80%

5天

+2.49%

1月

+3.35%

6月

-9.31%

今年开始到现在

-1.05%

1年

+178.45%

关键数据
10.757今开
11.250最高
4.85K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.74%换手率
10.830昨收
10.757最低
43.86K成交额
亏损市盈率静
0.31市净率
0.00%股息率 TTM
-56.45%ROA
196.70052周最高
1.48量比
-21.82M净利润
656.00K总股本
-1155.2209每股收益TTM
1.09Beta
-60.65%ROE
8.67052周最低
4.55%振幅
--毛利率
7.29M总市值
0.13回报/风险
5.63%风险率

TradingKey enVVeno Medical Corp股票评分

单位: USD 更新时间: 2026-07-02

操作建议

enVVeno Medical Corp当前公司基本面数据相对谨慎,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名215/387位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价12.50。中期看,股价处于上升通道。近一个月,市场表现一般,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

enVVeno Medical Corp评分

相关信息

行业排名
215 / 387
全市场排名
424 / 4565
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

enVVeno Medical Corp亮点

亮点风险
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
估值高估
公司最新PE估值-0.01,处于3年历史高位
机构减仓
最新机构持股184.36K股,环比减少34.20%

分析师目标

根据 1 位分析师
持有
评级
12.500
目标均价
+1517.29%
涨幅空间

enVVeno Medical Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

enVVeno Medical Corp简介

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代码NVNO
公司enVVeno Medical Corp
CEOBerman (Robert A)
网址https://envveno.com/

常见问题

enVVeno Medical Corp(NVNO)的当前股价是多少?

enVVeno Medical Corp(NVNO)的当前股价是 11.11。

enVVeno Medical Corp的股票代码是什么?

enVVeno Medical Corp的股票代码是NVNO。

enVVeno Medical Corp股票的52周最高点是多少?

enVVeno Medical Corp股票的52周最高点是196.70。

enVVeno Medical Corp股票的52周最低点是多少?

enVVeno Medical Corp股票的52周最低点是8.67。

enVVeno Medical Corp的市值是多少?

enVVeno Medical Corp的市值是7.29M。

现在enVVeno Medical Corp(NVNO)的股票是买入、持有还是卖出?

根据分析师评级,enVVeno Medical Corp(NVNO)的总体评级为signal_hold,目标价格为12.50。

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是多少

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是-1157.08。